1. Home
  2. VRTX vs ELV Comparison

VRTX vs ELV Comparison

Compare VRTX & ELV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRTX
  • ELV
  • Stock Information
  • Founded
  • VRTX 1989
  • ELV 1944
  • Country
  • VRTX United States
  • ELV United States
  • Employees
  • VRTX N/A
  • ELV N/A
  • Industry
  • VRTX EDP Services
  • ELV Medical Specialities
  • Sector
  • VRTX Technology
  • ELV Health Care
  • Exchange
  • VRTX Nasdaq
  • ELV Nasdaq
  • Market Cap
  • VRTX 96.6B
  • ELV 78.9B
  • IPO Year
  • VRTX 1991
  • ELV N/A
  • Fundamental
  • Price
  • VRTX $410.82
  • ELV $358.13
  • Analyst Decision
  • VRTX Buy
  • ELV Buy
  • Analyst Count
  • VRTX 25
  • ELV 14
  • Target Price
  • VRTX $493.64
  • ELV $405.31
  • AVG Volume (30 Days)
  • VRTX 1.7M
  • ELV 2.0M
  • Earning Date
  • VRTX 11-03-2025
  • ELV 10-21-2025
  • Dividend Yield
  • VRTX N/A
  • ELV 1.91%
  • EPS Growth
  • VRTX N/A
  • ELV N/A
  • EPS
  • VRTX 14.07
  • ELV 23.39
  • Revenue
  • VRTX $11,418,800,000.00
  • ELV $189,254,000,000.00
  • Revenue This Year
  • VRTX $10.90
  • ELV $12.49
  • Revenue Next Year
  • VRTX $9.57
  • ELV $5.45
  • P/E Ratio
  • VRTX $29.16
  • ELV $15.29
  • Revenue Growth
  • VRTX 10.46
  • ELV 10.21
  • 52 Week Low
  • VRTX $362.50
  • ELV $273.71
  • 52 Week High
  • VRTX $519.88
  • ELV $510.24
  • Technical
  • Relative Strength Index (RSI)
  • VRTX 61.10
  • ELV 73.45
  • Support Level
  • VRTX $400.74
  • ELV $316.01
  • Resistance Level
  • VRTX $411.91
  • ELV $357.00
  • Average True Range (ATR)
  • VRTX 8.84
  • ELV 8.41
  • MACD
  • VRTX 3.92
  • ELV 4.07
  • Stochastic Oscillator
  • VRTX 97.78
  • ELV 99.42

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About ELV Elevance Health Inc.

Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 46 million medical members as of June 2025. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.

Share on Social Networks: